| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K11533227 | CTRPv2 | pan-cancer | AAC | -0.025 | 0.5 |
| mRNA | Cytarabine | CTRPv2 | pan-cancer | AAC | -0.019 | 0.5 |
| mRNA | MLN2480 | CTRPv2 | pan-cancer | AAC | -0.035 | 0.5 |
| mRNA | Y-39983 | GDSC1000 | pan-cancer | AAC | 0.022 | 0.5 |
| mRNA | Erlotinib | UHNBreast | pan-cancer | AAC | -0.19 | 0.5 |
| mRNA | myricetin | CTRPv2 | pan-cancer | AAC | -0.025 | 0.5 |
| mRNA | Curcumin | CTRPv2 | pan-cancer | AAC | 0.023 | 0.5 |
| mRNA | SN-38 | GDSC1000 | pan-cancer | AAC | -0.022 | 0.5 |
| mRNA | tretinoin:navitoclax (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.023 | 0.5 |
| mRNA | tandutinib | CTRPv2 | pan-cancer | AAC | -0.024 | 0.5 |